For the quarter ending 2026-03-31, KROS had -$5,918K decrease in cash & cash equivalents over the period. -$3,602K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total segment revenue | - | - | 14,262 | - |
| Research and development-KER065Program Expenses | - | - | 1,345 | - |
| Research and development-Elritercept Program Expenses | - | - | 3,341 | - |
| Research and development-Cibotercept Program Expenses | - | - | 1,218 | - |
| Research and development-Preclinical Development Expenses | - | - | 1,700 | - |
| Compensation costs (excluding stock based compensation) | - | - | 9,568 | - |
| Stock-based compensation | - | - | 3,986 | - |
| Depreciation expense | - | - | 395 | - |
| Other segment items | - | - | 8,346 | - |
| Dividend income | - | - | 6,933 | - |
| Income tax (provision) benefit | - | - | -1,424 | - |
| Gain on disposal of fixed asset | - | -1 | 0 | 14 |
| Net income (loss) | -23,708 | -23,461 | -7,280 | 117,755 |
| Depreciation expense | 403 | 400 | 395 | 714 |
| Stock-based compensation expense | 6,199 | 7,305 | 3,986 | 17,405 |
| Non-cash lease expense | 636 | 622 | 609 | 1,179 |
| Accounts receivable | -3,167 | 75 | -12,324 | 13,074 |
| Prepaid expenses and other current assets | -15,672 | -141 | -4,434 | 557 |
| Current income tax receivable | - | 2,250 | - | - |
| Other assets | 0 | 0 | 0 | -2,056 |
| Accounts payable | -108 | -697 | -2,955 | 651 |
| Right-of-use assets and operating lease liabilities | 572 | 546 | 525 | 907 |
| Deferred revenue | -155 | - | -770 | 925 |
| Current tax liability | -4,147 | - | -2,174 | 6,321 |
| Accrued expenses and other current liabilities | -5,218 | -4,430 | -4,795 | -906 |
| Net cash provided by (used in) operating activities | -3,529 | -27,292 | 3,249 | 131,548 |
| Purchase of property and equipment | 73 | 134 | 132 | 1,285 |
| Net cash used in investing activities | -73 | -134 | -132 | -1,285 |
| Payment of issuance costs associated with issuance of common stock under the atm agreement-At The Market Offering | - | - | 0 | 0 |
| Proceeds from issuance of common stock-Secondary Offering | - | 0 | 0 | 0 |
| Payment of issuance costs | - | 0 | 0 | 0 |
| Proceeds from issuance of common stock-At The Market Offering | - | 0 | 0 | 0 |
| Payment of issuance costs associated with issuance of common stock under the atm agreement | - | 0 | - | - |
| Proceeds from issuance of common stock under the employee stock purchase plan | - | 0 | 138 | - |
| Repurchase of treasury stock | - | 375,000 | - | - |
| Payment of direct expenses associated with the treasury stock repurchase | 2,323 | 3,897 | - | - |
| Short-swing profit settlement | - | 139 | - | - |
| Proceeds from exercise of stock options | 7 | 127 | 2 | 21 |
| Net cash provided by (used in) financing activities | -2,316 | -378,631 | 140 | 21 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | -5,918 | -406,057 | 3,257 | 130,284 |
| Cash, cash equivalents and restricted cash at beginning of period | 288,864 | 694,921 | 561,380 | - |
| Cash, cash equivalents and restricted cash at end of period | 282,946 | 288,864 | 694,921 | - |
Keros Therapeutics, Inc. (KROS)
Keros Therapeutics, Inc. (KROS)